DelveInsight’s, “Hepatic Tumor Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and ...
In back-to-back studies published in Nature, researchers from Purdue University and Columbia University report a naturally ...
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production ...
ProQR Therapeutics N.V. (NASDAQ:PRQR) earns a spot in our list of the top 10 stocks under $5 that could triple. As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR) ...
Existing bacteria and archaea still our universal common ancestor’s ribosomal hibernation defense mechanism when nutrients ...
InvestorsHub on MSN
Sarepta shares jump after early clinical data from siRNA programs
Shares of Sarepta Therapeutics (NASDAQ:SRPT) climbed about 14% after the company released preliminary clinical results from ...
Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...
GSK is sourcing early-stage science across a wide range of technologies and disease areas, while placing more selective bets ...
Eascra Biotech, a nanomedicine startup, has won first place at the TechConnect Bio in Space Innovation Challenge, held during ...
Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund” ...
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ...
Rare diseases, defined in the U.S. as conditions affecting fewer than 200,000 people, can take years, if not decades, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results